Plitidepsin Combination Therapy for Coronavirus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Coronavirus infections, particularly COVID-19, lack effective therapeutic strategies, with existing agents showing varying efficacy and no clear strategies identified for managing the infection effectively.
Innovation Solution
The use of plitidepsin (PLD) in combination with one or more further CoV antiviral agents, such as calpain inhibitors, RNA polymerase inhibitors, or serine protease inhibitors, to treat Coronavirus infections, including COVID-19, by administering PLD with these agents concurrently, sequentially, or separately, to inhibit viral entry, replication, or fusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral agents are used to treat Coronavirus infection, then treatment coverage is provided, but efficacy is insufficient and no clear therapeutic strategy is identified
Solution Approach 1:
The patent combines plitidepsin with other antiviral agents (such as calpain inhibitors, RNA polymerase inhibitors, or serine protease inhibitors) to create a combination therapy regimen. This merging of multiple therapeutic agents addresses the insufficiency of single agents by targeting multiple viral processes simultaneously, thereby improving overall therapeutic efficacy and establishing a clear treatment strategy for Coronavirus infection
2Reliability
If combination therapy with PLD and other antiviral agents is used, then viral load reduction is improved, but treatment complexity increases
Solution Approach 1:
The combination therapy is administered in a segmented manner, allowing the multiple antiviral agents to be given at different times or in different sequences. This segmentation approach maintains the therapeutic benefits of combination therapy while reducing the immediate complexity burden on patients and healthcare systems
3Reliability
If multiple antiviral agents are administered in combination, then antiviral activity is retained and enhanced, but toxicity concerns arise
Solution Approach 1:
The patent optimizes the dosing parameters and administration schedules of plitidepsin in combination with other antiviral agents. By carefully adjusting concentrations, timing, and duration of each agent, the regimen maintains enhanced antiviral activity while minimizing cumulative toxicity through parameter optimization
Data Source
AI summary
The use of PLD with one or more further CoV antiviral agent(s) in the treatment of coronavirus (CoV) infection.